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 PREVALENCE AND PREDICTORS OF CHRONIC LIVER DISEASE IN AN 
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Lauder, Nicole Forbes, Krystn Wagner, Jose Salvana, Sharon Weissman, Pamela E. 
Jackson, Amanda Durante, and Andre N. Sofair.  Department of Internal Medicine, Yale 
University, School of Medicine, New Haven, CT. 
 
Chronic liver disease (CLD) is a leading cause of morbidity and mortality in HIV-
infected individuals. The purposes of this study were to determine the prevalence and 
etiologies of CLD in an urban HIV-infected population and to identify CLD risk factors.  
We conducted a retrospective chart review of 799 HIV-infected patients seen at four New 
Haven health centers from 2002 to 2003.  We applied the New Haven County Liver 
Study definition to identify patients with CLD.  65% were male, 44% were African 
American, and 23% were of Hispanic ethnicity.  The mean age was 45 years.  30% had a 
history of alcohol abuse.  35% reported injection drug use as their HIV risk factor. 
Heterosexual contact and men having sex with men (MSM) were reported in 31% and 
16% of cases.  50% of patients had a diagnosis of AIDS.  60% percent of patients had 
CLD.  Over 50% of cases of CLD were attributed to chronic hepatitis C (HCV), either 
alone or with coexisting alcoholic liver disease.  Alcoholic liver disease alone, hepatitis B 
virus (HBV), HAART-induced liver disease, and non-alcoholic liver disease (NAFLD) 
accounted for smaller percentages.  84% of patients were on HAART, but only 3.6% of 
patients with positive HCV or HBV serologies were on treatment for CLD.  75% of 
patients received pneumococcal and influenza vaccines, but only half of eligible patients 
received hepatitis A and B vaccines.  In multivariate analysis, alcohol abuse and positive 
HCV status were associated with CLD.  CLD is prevalent in our population.  Preventive 
care and treatment for CLD are being overlooked in many.  Vaccines, treatment for viral 
hepatitis, and strategies for reducing drug and alcohol abuse are priorities. 
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INTRODUCTION 
 
I. Epidemiology of HIV and AIDS 
An estimated 1,039,000 to 1,185,000 persons in the United States are currently 
living with HIV/AIDS, including 250,000 to 320,000 who are unaware of their serostatus 
[1].  Each year, approximately 40,000 new HIV infections occur, 70% of which occur 
amongst men, although a growing number of women are affected yearly [2].  Men who 
have sex with men (MSM) currently represent the largest proportion of cases by 
transmission category on both national and state-wide levels (49% in 2003), but 
heterosexuals and intravenous drug users are also significantly affected (34% and 19%, 
respectively in 2003) [2]. 
In the absence of treatment, HIV progresses to full-blown AIDS in the majority of 
individuals.  It is estimated that 10 to 12 percent of HIV-infected patients progress to 
AIDS within the first 5 years following infection, and over 50% develop AIDS within 10 
years [3,4]  Approximately five percent of individuals have stable CD4+ T cell counts 
and no symptoms even after 12 or more years [5].  The progression from HIV to 
untreated AIDS is recognized as being universally fatal.  Only a very small percent of 
people with untreated AIDS survive five years after they are diagnosed. 
Reports by the CDC have documented steep declines in AIDS mortality within 
the United States over the last decade (from 50,000 deaths per year in 1995 to 16,000 in 
2004 [2,6].  This trend is mostly attributed to the advent of potent antiretroviral therapy, 
which gained widespread acceptance and use in the mid 1990s.  In recent years, however, 
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the rate of decline has slowed, due to emerging problems such as unequal access to HIV 
care, incomplete adherence to therapeutic regimens, and viral resistance to therapy. 
The distribution of HIV and AIDS cases by demographic characteristics has also 
changed substantially over time.  The disease disproportionately affects ethnic minorities, 
such as African Americans and Hispanics, women, and adolescents, and recent studies 
have shown that infection and mortality rates are in fact increasing within several subsets 
of these populations.  The largest proportional increase in new cases has occurred 
amongst heterosexual women, from approximately 9% in 1992 to 27% in 2003.  In 
addition, the proportion of cases in African Americans has increased from 25% to 50% of 
the total and that of Hispanics has increased 14% to 20% over two decades.  Minority 
Americans currently represent the majority of new cases (71%), as well as the largest 
proportion of people living with AIDS (64%).   This puts certain populations, such as 
minority MSM and minority women at particularly high risk [2, 6-10]. 
 
II. Epidemiology of Chronic Liver Disease (CLD) 
Chronic liver disease (CLD) is one of the ten leading causes of mortality in the 
United States, and accounts for over 25,000 deaths each year [11,12].  Although overall 
mortality from CLD has shown a gradual decline over the last three decades, death rates 
within certain subgroups have increased over time.  For example, CLD deaths attributable 
to hepatitis C increased 220% between 1993 and 1998, while mortality from other causes 
of CLD decreased or remained unchanged over the same time period [12].  Cirrhosis and 
CLD also disproportionately affect men, certain ethnic minorities, and the middle-aged 
population.  In fact, CLD ranks as the fifth leading cause of death in men between the 
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ages of 45 and 64 years, and accounts for more than twice as many deaths amongst 
Native Americans, Hispanics, and African Americans than other ethnic groups [11].  
Alcohol and viral hepatitis are considered the two most important etiologies for CLD; 
however, NAFLD (non-alcoholic fatty liver disease) is increasingly being recognized as a 
common cause.  Risk factors for chronic liver disease include low socioeconomic status, 
drug use, exposure to environmental and industrial toxins, and genetic predisposition. 
 Alcohol use is one of the most significant causes of chronic liver disease in the 
United States.  Alcoholic liver disease can be classified into three distinct, often 
overlapping histologic categories: steatosis, acute alcoholic hepatitis, and cirrhosis.  
While steatosis is often asymptomatic and thought to be reversible with abstinence, 
hepatitis is much more severe, with up to 80% of patients progressing to cirrhosis or 
hepatocellular carcinoma upon continued ingestion of alcohol [13].  There is a direct 
correlation between alcohol consumption and liver-related mortality [14].  Of the 14 
million Americans who meet criteria for alcoholism, 2 million are suspected of having 
significant liver disease.  It is estimated that men who drink more than 80 g/d of ethanol 
for several years will be at substantial risk of developing clinical liver disease [15].  
Women who ingest a similar amount are up to four times more likely than men to 
develop alcoholic liver disease, and they exhibit a tendency to progress to cirrhosis even 
with abstinence [16,17]. 
Hepatitis C virus is the single most common cause of chronic liver disease, and 
poses a significant public health problem in the United States and worldwide.  Infection 
with HCV causes chronic hepatitis in 80% of patients, and up to 25% of monoinfected 
individuals develop cirrhosis and end-stage liver disease within the next thirty to forty 
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years [18].  Chronic liver disease from HCV infection is currently the most common 
indication for liver transplantation, accounting for up to 35% of orthotopic transplant 
recipients [19].  Although treatment response varies by genotype, treatment for HCV 
genotype 1 (the genotype that infects the vast majority of individuals) has thus far been 
rather disappointing, with the best response rates to interferon and ribavirin reported at 
40% [20, 21].  Alcohol use and HCV infection frequently coexist in patients, and many 
studies have shown that their effects are synergistic in promoting liver damage, hastening 
both cirrhosis and hepatocellular carcinoma [22,23]. 
Although the development of the hepatitis B vaccine in the mid-1980’s is 
considered one of the major achievements of modern medicine, HBV infection remains 
an important cause of morbidity and mortality worldwide.  One analysis found that the 
rate of HBV-related hospitalizations, cancers, and deaths in the United States had more 
than doubled over the last decade [24].  The manifestations of chronic HBV infection 
range from an asymptomatic carrier state to chronic hepatitis, cirrhosis, and 
hepatocellular carcinoma.  Long term studies have shown that the majority of individuals 
who are HbsAg positive remain asymptomatic [25]; however, there is still approximately 
a 15% lifetime risk of developing cirrhosis or hepatocellular carcinoma [26].    Like 
HCV, treatment for HBV has been suboptimal, which may be complicated by the fact 
that infected patients often have comorbid disease such as chronic HCV infection and 
alcoholic hepatitis. 
The prevalence and risk factors for NAFLD are not well-described, although it is 
a condition currently under active investigation.  NAFLD is frequently associated with 
obesity, insulin resistance, type 2 diabetes mellitus, and hyperlipidemia.  In unselected 
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populations, the prevalence is reported to range between 3 and 23 percent [27, 28]; 
however, in patients with diabetes, the prevalence may be as high as 63% [29].  
Symptomatic NAFLD is extremely uncommon, but there remains a small risk of 
cirrhosis, hepatocellular carcinoma, and mortality from end stage liver disease, reported 
in retrospective studies as occurring in fewer than 3% of patients with NAFLD [30].  
 
III. Relationship between CLD and HIV 
Since the introduction of HAART, the life expectancy of patients with HIV has 
dramatically increased [31, 32].  The use of HAART has led to declines in opportunistic 
infections and acute bacterial infections, both of which were implicated in the majority of 
AIDS-related deaths during the pre-HAART era.  As a result of increased longevity, 
mortality and morbidity due to other co-existing conditions, such as liver cirrhosis, renal 
failure, cardiac disease, and cancer, are assuming greater importance.   
End-stage liver disease in particular has become a leading cause of death amongst 
HIV-infected patients, accounting for up to 50% of deaths amongst hospitalized HIV 
positive patients [33]. Most etiologies of liver disease in these patients are similar to 
those in the general population, such as chronic HCV, chronic HBV, and alcoholic 
hepatitis.  However, the high risk of hepatotoxicity from antiretroviral drugs and the 
effects of immunosuppression on the natural courses of these diseases present additional 
challenges in HIV-infected patients. 
Due to the shared route of transmission, coinfection with HCV and HIV has 
become an especially common diagnosis, reported to affect up to 30% of all HIV-infected 
patients [34].  Coinfection is particularly prevalent in IV drug users, whose rates of 
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coinfection may range from 75% to 90% [35-37].  Several studies have established that 
HIV infection modifies the natural history of HCV infection, accelerating the progression 
from chronic hepatitis to cirrhosis and end-stage liver disease and placing HIV-positive 
patients at increased risk for morbidity and mortality secondary to these conditions. [33, 
38-41].  The effect of HCV infection on the natural history of HIV, however, is a much 
more controversial issue and results have been conflicting thus far.  While some studies 
suggest that certain HCV genotypes or higher HCV viral loads are associated with more 
rapid progression to AIDS or death [42-44], others detect no correlation between HCV 
infection and progression of HIV [45-47]. 
Like HCV, hepatitis B virus is transmitted through blood and body fluids, and 
therefore may be found in HIV-infected populations.  In the absence of treatment for 
HBV, there is an increased frequency of cirrhosis in coinfected patients compared with 
HIV or HBV-monoinfected patients [48, 49].  Liver-related mortality in HIV/HBV 
coinfection is reported to be 14-fold higher than that for either virus alone, and patients 
who have HIV are three to six times more likely to develop chronic hepatitis B following 
occult infections compared with patients  who do not have HIV [50].  There are several 
medications, such as lamivudine and tenofovir, which are approved to treat both HIV and 
HBV. 
Although clinical manifestations of liver toxicity are somewhat rare from 
antiretroviral therapy alone, mild to moderate elevations in liver transaminases (AST and 
ALT) are relatively common in patients on HAART.  Chronic viral hepatitis, alcohol 
ingestion, and use of other drugs are co-factors that increase the incidence of elevated 
hepatic markers in HIV patients.  Several studies have, furthermore, suggested that HCV 
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increases the risk of hepatotoxicity from antiretroviral regimens [51, 52], which 
complicates the fact that suppression of HIV viral load in coinfected patients may 
decrease the rate of HCV progression [53].  This is particularly true nevirapine, full-dose 
ritonavir, and tipranavir, which are associated with increased risk of hepatotoxicity in 
coinfected patients.     Although the overwhelming evidence supporting the benefit of 
antiretroviral therapy indicates that HAART should not be withheld in coinfected 
patients, liver injury may be one of the major limiting factors in the effectiveness of 
therapy. 
Alcohol abuse frequently coexists with HIV, and may play a significant role in 
determining patient outcome.  Alcoholism is associated with greater mortality and 
morbidity, increased symptom burden, poorer compliance with antiretroviral therapy, 
more rapid progression of disease, increased severity of comorbid disease (particularly 
chronic HCV infection), and greater risk of viral resistance [54-57].  Because alcohol 
abuse, HCV, and HBV may often act synergistically in accelerating liver damage, HIV-
infected patients with multiple risk factors for chronic liver disease are at particular risk 
for liver-related morbidity and mortality. 
Risk factors for steatohepatitis in the non-HIV population are also valid in 
individuals with HIV.  However, HIV-infected patients who are treated with NRTIs and 
d4T in particular may be especially prone to severe macrosteatosis.  Protease inhibitors 
(PIs) and nucleoside reverse transcriptase inhibitors (NRTIs) appear to act synergistically 
in development of HIV-related lipodystrophy, and the length of therapy with these 
medications positively correlates with the amount of lipodystrophy [58].  Consequently, 
HIV-positive patients on HAART tend to have a higher incidence of insulin resistance 
 
 8
and visceral abdominal obesity.  Furthermore, insulin resistance and the incidence of 
lipoatrophy are increased significantly in patients with HIV/HCV coinfection compared 
with those with HIV alone, which may also predispose to NAFLD and lead to hepatic 
fibrosis [59]. 
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SPECIFIC AIMS 
 
The burden of chronic liver disease is considerable in HIV-infected patients; however, 
very few studies have described this phenomenon in an entire urban HIV population.  
Therefore, the purposes of this study were: 
1. To calculate the prevalence and etiologies of chronic liver disease in urban 
HIV clinics. 
2. To identify risk factors associated with an increased risk of chronic liver 
disease in this population. 
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METHODS 
 
Subjects.  This study is a retrospective chart review of HIV-infected patients followed at 
four different urban health centers in New Haven (Nathan Smith Clinic, Hill Health 
Center, St. Raphael’s Hospital/Haelen Center, and Fair Haven Clinic and Health Center).  
Patients were included if they were HIV seropositive, and had attended clinic between 
2002 and 2003; abstracted data, however, was not limited to this twelve month period but 
also included information prior to 2002 and following 2003.  Any data that was dated 
past January 1, 2006 was not abstracted.  A 50% random sample was used at Nathan 
Smith Clinic and the St. Raphael’s Hospital/Haelen Center, while 100% samples were 
included from the other sites.  The chart review was started prior to my involvement in 
the study; therefore, most of the abstraction at Hill Health Center and Fair Haven Clinic 
was carried out by other individuals, while abstraction at Nathan Smith Clinic and Haelen 
Center was completed by me.  
 
Data Collection.  Data were abstracted from the patient charts by trained individuals 
using a standard data collection form; charts were in the form of either computerized or 
paper records depending on site.  Abstracted data included demographic characteristics, 
such as age, gender, race/ethnicity, height, weight, and town of residence; social practices 
such as HIV exposure and alcohol abuse; clinical and laboratory data regarding liver 
function, HIV progression, hepatitis and HIV serology, vaccinations (hepatitis A and B, 
pneumococcal, and influenza), and treatment history.  Alcohol abuse was defined as 
alcohol intake of > 3 drinks per day for 10 years, hospitalization or rehabilitation, 
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withdrawal, history of DUI, or physician impression of alcoholism.  Liver-related clinical 
data consisted of biopsy results, clinical events (hepatic encephalopathy, variceal bleed, 
ascites, spontaneous bacterial peritonitis (SBP), hepatorenal syndrome, or cholangitis), 
and diagnostic imaging results (US, CT, MRI, liver/spleen scan, or endoscopy).  In 
addition, liver transaminases (AST, ALT, alkaline phosphatase, and GGT), iron studies, 
and triglycerides were recorded (first, last, and all abnormal tests ≥ 6 months apart).  
HIV-related data included immunologic markers recorded at intervals of ≥ 6 months 
(CD4, viral load, WBC, % lymphocyte) and diagnosis of AIDS, based on AIDS-defining 
illnesses (ADIs) or CD4 count.  ADIs were defined according to the CDC 1993 revised 
classification system [60].  Treatment for chronic liver disease (CLD), as well as 
antiretroviral medication history, was recorded.  Abstracted information for CLD 
included treatment regimen (standard interferon alfa, pegylated interferon alfa, ribavirin, 
lamivudine, adefovir, or Cellcept), length of treatment, reason for discontinuation, and 
treatment response (ETR and SVR).  Data regarding antiretroviral medication included 
drug name, dose, and duration of use.   
 
Assessment of CLD.  Patient charts were screened for evidence of CLD using the New 
Haven County Liver Study (NHCLS) case definition.  This study defines chronic liver 
disease as: two sets of abnormal LFTs (elevated ALT, elevated AST, or concurrently 
elevated alkaline phosphatase and GGT) ≥ 6 months apart, a liver-related clinical event 
(hepatic encephalopathy, variceal bleed, ascites, or SBP), a diagnostic imaging result 
indicating chronic hepatitis, cirrhosis, or hepatocellular or cholangiocarcinoma, or a 
biopsy result consistent with chronic hepatitis, cirrhosis, or hepatocellular or 
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cholangiocarcinoma.  The classification of cirrhosis was made if biopsy showed features 
consistent with cirrhosis, or if diagnostic imaging studies showed positive signs such as 
nodular/shrunken liver, portal hypertension, colloid shift, ascites, varices/collaterals, 
and/or cirrhosis.  In those patients who satisfied the case definition for CLD, a diagnostic 
impression of etiology was made based on clinic notes and laboratory data.  Etiologies 
included alcoholic liver disease (based on classification of alcohol abuse), chronic 
hepatitis B, chronic hepatitis C, HIV antiretroviral induced liver disease, or NASH/fatty 
liver.  Chronic hepatitis B was defined as positive HBV sAg or positive HBV eAg on 
serology.  Chronic hepatitis C was defined as positive ELISA, RIBA, or PCR.  “Possible” 
HCV infection was defined as positive ELISA or RIBA results, without quantitative or 
qualitative PCR results or genotype results.  “Definite” HCV infection was identified as 
positive PCR or HCV genotype results.  Patients could be classified as having more than 
one etiology.         
 
Assessment of Clinical Care.  Markers of clinical care included treatment for CLD and 
HIV, gastroenterology referrals, and vaccination history.  Because CLD treatment was 
defined as antiviral therapy, only patients with evidence of HCV infection or HBV 
infection were included in this analysis.  Patients included in HAV or HBV vaccination 
analysis were those who did not have serological evidence of chronic disease or previous 
immunity.  Only one dose of each vaccine was required to qualify a patient as having a 
positive vaccination history. 
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Statistical Analysis.  Descriptive statistics were expressed as means and percentages for 
continuous and categorical variables, respectively.  CLD was the outcome measured in all 
analyses; univariate chi-squared tests were used to determine predictors.  Baseline 
variables examined were age (dichotomous variable expressed as >/=mean age or <mean 
age); gender; race (white, African-American, or other); ethnicity (Hispanic/Latino or not 
Hispanic/Latino); HIV risk factor (IDU, MSM, IDU/MSM, heterosexual contact, or 
other); alcohol abuse; CD4 count (dichotomous variable expressed as <200 or >/=200); 
viral load (dichotomous variable expressed as <10,000or >/=10,000); infection with 
HCV; use of antiretroviral therapy; and AIDS diagnosis. 
 
Liver function test abnormalities were examined in several different ways.  For patients 
who were on HAART and had AST or ALT values recorded before and after initiation of 
treatment, “pre-HAART” and “post-HAART” values were recorded.  The pre-HAART 
values were those that were closest to initiation of HAART; these were defined as that 
patient’s baseline LFTs.  The post-HAART values were the highest values recorded 
following initiation of HAART.  The means of these pre-HAART and post-HAART 
values, as well as the mean percent change (delta), was described.  The mean values and 
deltas were also expressed as function of whether patients had CLD or chronic HCV 
infection. 
 
HIV-related tests (CD4 count and viral load) were only used in statistical analyses if they 
were recorded prior to initiation of HAART or in the absence of antiretroviral therapy. 
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RESULTS 
 
 Data from a total of 799 patients were reviewed (262 patients from Nathan Smith 
Clinic; 244 patients from Hill Health Center; 237 from St. Raphael’s Hospital/Haelen 
Center; and 56 from Fair Haven Clinic and Health Center).  Demographic characteristics 
of the study population are shown in table 1, both as a whole and separately by clinic.  
The majority of patients were male (65%) and African-American (44%), and these  
 
TABLE 1: DEMOGRAPHIC CHARACTERISTICS 
 ALL PTS* 
(N=799) 
NSC 
(N=262) 
HHC 
(N=244) 
HC/HSR 
(N=237) 
FHCHC
(N=56) 
Gender (%) 
 
Male 
Female 
Transgender 
Unknown 
 
64.7 
34.0 
0.6 
0.7 
61.1 
37.0 
1.1 
0.8 
70.9 
27.5 
0 
1.6 
 
62.5 
37.1 
0.4 
0 
62.5 
35.7 
1.8 
0 
Age (mean; years, range) 44.7  
(8-81) 
45.9  
(26-75) 
43.5  
(8-67) 
45.8  
(28-81) 
40.0  
(9-62) 
Race (%) 
 
White 
Black 
Asian 
Other 
Unknown 
 
20.1 
44.1 
0.5 
2.4 
32.9 
19.9 
29.8 
0 
5.3 
45.0 
10.3 
58.2 
0.8 
0.4 
30.3 
32.1 
50.2 
0.8 
1.3 
15.6 
14.3 
23.2 
0 
1.8 
60.7 
 
Ethnicity (%) 
 
Hispanic/Latino 
Not Hispanic/Latino 
Unknown 
 
22.7 
51.9 
25.4 
14.9 
17.2 
67.8 
28.3 
68.9 
2.8 
16.5 
76.3 
7.2 
60.7 
37.5 
1.8 
Town (%) 
 
New Haven 
New Haven County 
Non-New Haven County 
Unknown 
 
61.6 
19.9 
6.9 
11.6 
37.0 
20.2 
15.7 
27.1 
82.0 
10.6 
0.4 
7.0 
62.0 
31.2 
4.7 
2.1 
85.7 
10.7 
3.6 
0 
Alcohol 
Abuse (%) 
Yes 
No 
Unknown 
30.4 
59.0 
10.6 
24.8 
64.1 
11.1 
34.4 
59.0 
6.6 
32.9 
50.6 
16.5 
28.6 
69.6 
*NSC = Nathan Smith Clinic (Yale New Haven Hospital) 
1.8 
  HHC = Hill Health Center 
  HC/HSR = Haelen Center (Hospital of St. Raphael) 
  FHCHC = Fair Haven Clinic and Health Center 
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findings were consistent across all four clinics.  At Hill Health Clinic and Haelen Center, 
over 50% of patients were African-American.  The mean age was 45 years.  Overall, 
approximately 23% of patients were found to be of Hispanic or Latino heritage, although 
there were many patients for whom ethnicity was not reported.  Ethnicity varied widely 
by clinic, with Fair Haven Clinic having the largest proportion of Hispanic/Latino 
patients (61%).  Although the majority of patients from all health centers were from New 
Haven (62%), Nathan Smith Clinic had the largest percentage of patients from outside 
New Haven County.  This finding is consistent with the fact that Nathan Smith Clinic is a 
university affiliate and therefore likely to receive a substantial number of referrals.  
Approximately 30% of patients were found to have a history of alcohol abuse.     
 Table 2 summarizes HIV-related characteristics.  The majority of patients in this 
study population acquired HIV through intravenous drug use (35%); at Hill Health 
Center, IDU made up over 50% of cases by transmission category.  Heterosexual contact 
and MSM were also major sources of HIV exposure, accounting for 31% and 16% of 
cases, respectively.  The mean pre-HAART CD4 count in this population was 296, and 
the mean pre-HAART viral load was 116,233.  Over half of all patients were diagnosed 
with AIDS, and of these, most qualified by having a CD4 count of 200 or below or by 
having both an AIDS-defining illness as well as a CD4 count under 200. 
 Liver-related characteristics are recorded in table 3.  About 60% of patients met 
the CLD case definition; of these, the majority qualified by having two sets of abnormal 
LFTs six months apart.  Of note, 84% of all patients were found to have abnormal LFTs 
at some point in their clinical care; however, only 57% of these met the CLD case  
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TABLE 2: HIV CHARACTERISTICS 
 ALL PTS 
(N=799) 
NSC 
(N=262) 
HHC 
(N=244) 
HC/HSR 
(N=237) 
FHCHC 
(N=56) 
HIV Exposure (%) IDU 
MSM 
MSM/IDU 
*CD4 count included only if patient had values recorded prior to ART;  
  N=666 (all), N=246 (NSC), N=195 (HHC), N=181 (HC/HSR), N=44 (FHCHC) 
†Viral load included only if patient had values recorded prior to ART;  
  N=603 (all), N=224 (NSC), N=183 (HHC), N=152 (HC/HSR), N=44 (FHCHC) 
°AIDS-defining illness 
 
 
TABLE 3: LIVER-RELATED CHARACTERISTICS 
  ALL PTS 
(N=799) 
NSC 
(N=262) 
HHC 
(N=244) 
HC/HSR 
(N=237) 
FHCHC
(N=56) 
CLD case  
definition (%) 
Yes 
    Biopsy* 
    Imaging* 
    Clinical Event* 
    LFTs* 
No 
Unknown 
59.7 
    8.4 
    13.9 
    3.9 
    94.1 
38.8 
1.5 
57.6 
    15.9 
    20.5 
    5.3 
    94.7 
42.4 
0 
65.2 
    2.5 
    8.8 
    3.8 
    96.2 
34.8 
0 
57.8 
    8.1 
    14.8 
    3.4 
    90.6 
37.1 
5.1 
53.6 
    3.3 
    3.3 
    0 
    96.7 
46.4 
0 
HCV Status (%) 
 
Positive 
     Definite 
     Possible 
Negative 
Unknown 
39.8 
    56.3 
    43.7 
52.8 
7.4 
42.4 
    64.0 
    36.0 
48.9 
8.8 
44.7 
    56.9 
    43.1 
43.8 
11.5 
34.2 
    53.1 
    46.9 
63.7 
2.1 
30.4 
    17.6 
    82.4 
64.3 
5.4 
HBV Status (%) Positive  
Negative 
Unknown 
4.8 
83.6 
11.6 
5.3 
85.1 
9.5 
3.7 
78.3 
18.0 
6.3 
84.4 
9.3 
0 
96.4 
3.6 
LFTs† 
(mean values, range) 
Baseline pre-ART ALT 
Baseline pre-ART AST 
 
Baseline post-ART ALT 
Baseline post-ART AST 
46 (4-636) 
52 (5-688) 
 
65 (2-638) 
73 (7-998) 
 
 
 
*Patients may qualify for CLD case definition by more than one criteria. 
†Significance testing revealed that p<0.0001 between mean pre-HAART and mean post-HAART LFTs. 
Heterosexual 
Other 
Unknown 
34.5 
16.2 
1.0 
32.8 
17.6 
0.4 
31.3 
0.8 
16.2 
27.1 
1.5 
20.6 
50.4 
7.8 
2.1 
22.9 
0 
16.8 
23.6 
22.4 
0.4 
43.0 
0 
10.6 
19.6 
19.6 
1.8 
37.5 
3.6 
17.9 
CD4 count (mean, range)*  296  
(1-1520) 
292  
1-1520) 
307 
 (2-1155) 
274  
(2-1163) 
368  
(1-1391) 
Viral load (mean, range)† 116233  
(1-4100K) 
104796  
(50-750K) 
78262  
(50-1380K) 
187026  
(50-4100K) 
87817  
(400-817K) 
Yes 
     CD4 count 
     ADI°     
Both 
     Unknown 
52.2 
    50.8 
    6.5 
    36.7 
    6.0 
49.2 
   53.5 
   8.5 
   30.2 
   7.8  
51.6 
   54.8  
59.5 
   45.4 
37.5 
   47.6 
   3.2 
   30.9 
   11.1 
   7.8  
   46.8 
   0 
   4.8 
   42.8 
   4.8 
No 43.4 44.3 46.7 35.0 60.7 
AIDS (%) 
 
Unknown 4.4 6.5 1.7 5.5 1.8 
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definition through the more stringent LFT criterion.  Forty percent of patients were HCV 
positive by serology, and of these patients, 56% were categorized as having “definite” 
infection (PCR or genotype results) while the rest had only ELISA or RIBA results and 
were therefore classified as having “possible” infection.  Over 81% of patients with a 
history of intravenous drug use tested positive for HCV, whereas only 11% of men who 
have sex with men and 17% of patients with heterosexual HIV risk factors had positive 
HCV serologies (data not shown).  Only about 5% of patients had chronic HBV by 
serology.  Mean baseline pre-HAART ALT and AST were significantly lower than mean 
baseline post-HAART ALT and AST (p<0.0001).   
Table 4 describes the etiologies for CLD in the subset of patients who met the 
NHCLS case definition.  Greater than 50% of patients had chronic liver disease as a 
result of hepatitis C, either alone or with coexisting alcoholic liver disease.  Alcoholic 
liver disease alone made up a substantial proportion of the total number of patients with  
 
TABLE 4: CLD ETIOLOGY 
 ALL PTS 
(N=488) 
NSC 
(N=151) 
HHC 
(N=159) 
HC/HSR 
(N=147) 
FHCHC 
(N=31) 
HCV 40.8  37.8 55.4 27.9 41.9 
HCV/Alcohol 10.3 11.9 5.0 15.7 3.2 
Alcohol 8.6 4.0 7.6 14.3 9.7 
HBV/HCV 3.5 6.6 1.9 0 3.2 
HBV 2.3 1.3 2.5 2.7 3.2 
NASH 2.1 1.3 0.6 4.8 0 
HAART-induced liver disease 1.6 0 3.1 0.7 6.5 
Alcohol/HBV 1.0 2.0 0 1.3 0 
HCV/HAART 1.0 0 2.5 0 3.2 
HCV/NASH 0.8 2.6 0 0 0 
Alcohol/HCV/HBV 0.4 0 0 1.3 0 
Alcohol/HAART 0.4 0 0 0.7 3.2 
HBV/HAART 0.4 0 1.3 0 0 
Other 3.0 4.0 4.4 0 6.5 
Unknown 23.8 28.5 15.7 26.6 19.4 
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CLD (8.6%), but the percentage varied widely by clinic (4% to 14.3%).  Although HBV 
alone only accounted for 2.3% of the total population, a number of patients were 
coinfected with HBV and HCV.  Other etiologies for chronic liver disease (including 
HAART-induced liver disease and NAFLD) accounted for smaller percentages; however, 
almost 18% of patients were found to have more than one etiology for their liver disease. 
 Table 5 summarizes the clinical care provided to this study population.  
Approximately 84% of patients were treated with HAART; however, only a very small 
percentage of patients who were HCV or HBV positive underwent treatment for CLD  
 
 
TABLE 5: CLINICAL CARE 
  ALL PTS 
(N=799) 
NSC 
(N=262) 
HHC 
(N=244) 
HC/HSR 
(N=237) 
FHCHC 
(N=56) 
HAART (%) Yes 
No 
83.5 
16.5 
79.0 
20.0 
79.5 
20.5 
91.1 
8.9 
89.3 
10.7 
CLD treatment (%)* 
 
Yes 
No 
3.6 
96.4 
8.4 
91.6 
0.9 
99.1 
1.1 
98.9 
0 
100 
Gastroenterologist (%) Yes 
No 
Unknown 
3.7 
93.9 
2.34 
2.7 
96.6 
0.7 
6.6 
92.2 
1.2 
5.9 
94.1 
0 
12.5 
87.5 
0 
Vaccines (%) 
     Pneumococcal 
 
 
Yes 
No 
Unknown 
 
74.6 
19.4 
6.0 
 
53.0 
44.3 
2.7 
 
80.3 
9.4 
10.3 
 
87.8 
5.5 
6.7 
 
94.6 
5.4 
0 
 
     Influenza 
 
Yes 
No 
Unknown 
 
77.7 
16.2 
6.1 
 
71.4 
26.0 
2.6 
 
72.1 
17.6 
10.3 
 
87.3 
5.5 
7.2 
 
91.1 
8.9 
0 
      
     Hepatitis A† 
 
 
 
Yes 
No 
Unknown 
N=346 
50.9 
36.7 
12.4 
N=126 
41.3 
57.1 
1.6 
N=82 
31.7 
54.9 
13.4 
N=120 
74.2 
0.8 
25.0 
N=18 
50.0 
50.0 
0 
 
     Hepatitis B† 
 
 
 
Yes 
No 
Unknown 
N=317 
49.2 
26.2 
24.6 
N=94 
44.7 
51.1 
4.2 
N=95 
60.0 
29.5 
10.5 
N=95 
32.6 
2.1 
65.3 
N=33 
78.8 
15.1 
6.1 
*Patients only included if they were HCV positive (both “possible” and “definite”) or HBV positive;  
  N=338 (all), N=119 (NSC), N=112 (HHC), N=90 (HC/HSR), N=17 (FHCHC) 
†Patients were only included if they did not have evidence of current infection or prior immunity. 
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(3.6%).  Treatment for CLD varied significantly by clinic, with the largest percentage 
(8.4%) being treated at Nathan Smith Clinic.  Gastroenterology referrals were provided to 
between 2.7% and 12.5%  of patients, depending on clinic.  With respect to vaccination 
history, 75% and 78% of patients had documented receipt of pneumococcal and influenza 
vaccines, respectively.  However, only about half of patients who did not have evidence 
of chronic HAV or HBV infection or previous immunity received vaccinations against 
these pathogens.  The history of vaccination varied widely depending on specific clinic; 
at Haelen Center, almost three-fourths of patients received the hepatitis A vaccine, and at 
Fair Haven Clinic, approximately 79% of patients were vaccinated against hepatitis B.   
 In table 6, antiretroviral therapy and liver function tests are compared in patients 
who either do or do not meet the CLD case definition, as well as in patients who do or do 
not have serological evidence for chronic HCV infection.  The proportion of patients on 
ART was similar in the group of patients that meet the case definition for CLD as in 
those who do not.  The mean post-HAART LFTs were significantly higher than the mean 
pre-HAART LFTs in patients who had CLD (p<0.0001), as well as in patients who were 
HCV positive (p<0.0001). 
 
TABLE 6: LIVER-RELATED CHARACTERISTICS FOR SUBSETS 
 CLD  No CLD  HCV  No HCV 
 
ART 
 
Yes 
No 
 
(N=477) 
86.4 
13.6 
(N=310) 
80.0 
20.0 
 
 
 
 
 
 
 
 
 LFTs† Baseline pre-ART ALT 
Baseline pre-ART AST 
 
Baseline post-ART ALT 
Baseline post-ART AST 
55.4 
61.6 
 
81.6 
91.0 
29.9 
34.4 
 
35.0 
40.6 
59.1 
68.3 
 
87.9 
103 
38.6 
41.8 
 
51.0 
54.3 
†Significance testing revealed that p<0.0001 between mean pre-HAART and mean post-HAART LFTs for 
  patients with CLD, as well as patients with HCV. 
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The results of univariate chi-squared analysis are shown in table 7.  Mean age 
greater than or equal to 45 years; male gender; history of alcohol abuse; HIV risk factor  
of MSM, intravenous drug use, or heterosexual contact with an HIV-positive individual; 
positive HCV status (and, more specifically, positive PCR or genotype results); treatment 
with HAART; and diagnosis of AIDS were all significantly associated with an increased 
risk of chronic liver disease by the NHCLS case definition.  Multivariate analysis was 
performed using four different models and is shown in Table 8.  The first model included 
all patients and found alcohol abuse and HCV status to be the only significant 
independent risk factors for CLD.  The second model looked at predictors of CLD in 
patients with HCV alone and found that treatment with HAART was the only significant 
risk factor.  The last two models included patients with “definite” HCV and patients with 
neither HCV or HBV, respectively; none of the risk factors were significant. 
 
TABLE 7: PREDICTORS OF CLD (UNIVARIATE) 
Age Age >45 yrs p = 0.01 
Gender Male p = 0.006 
Alcohol Abuse Positive p < 0.001 
HIV Risk Factor MSM 
IDU 
Heterosexual Contact 
p < 0.001 
p <0.001 
p <0.001 
HCV status Positive p < 0.001 
HCV category Definite p < 0.001 
ART Yes p = 0.018 
AIDS Yes p = 0.032 
Race  p = 0.595 
Ethnicity  p = 0.420 
CD4 count  p = 0.728 
Viral Load  p = 0.611 
 
TABLE 8: PREDICTORS OF CLD (MULTIVARIATE) 
MODEL INCLUSION CRITERIA PREDICTORS P-VALUES 
Model 1 All patients Alcohol abuse 
HCV status 
p = 0.02 
p < 0.0001 
Model 2 HCV-positive patients ART p = 0.03 
Model 3 “Definite” HCV infection none  
Model 4 Patients with no HCV or HBV infection none  
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DISCUSSION 
 
In this large, urban cohort of HIV-infected patients in New Haven County, we 
observed a high prevalence of chronic liver disease.  Sixty percent of individuals in our 
study population qualified as having CLD according to the New Haven County Liver 
Study case definition.  The most common causes of CLD were chronic hepatitis C and 
alcoholic liver disease, which together accounted for almost 60% of percent of cases.  
These findings are in agreement with prior studies, which have reported similar 
conclusions regarding the prevalence and etiologies for chronic liver disease in HIV-
infected populations [34-37]. 
HIV/HCV coinfection was extremely common in our cohort.  Approximately 
40% of the total population was found to have positive HCV serologies, and over half of 
all cases of CLD were attributed to chronic hepatitis C (with or without coexisting 
alcoholic liver disease).  HCV infection was particularly common in patients who 
reported a history of intravenous drug use, accounting for over 80% of this group.  This 
finding was similar to that in several previous studies, which reported coinfection rates of 
between 75% and 90% in intravenous drug users [35-37].   Patients with positive HCV 
serologies were found to have higher liver function tests than patients who were not 
infected with HCV, both prior to the initiation of HAART as well as after starting 
treatment. 
In our study population, HAART-induced liver toxicity did not account for a 
substantial proportion of cases of chronic liver disease.  HAART alone was attributed to  
only 1.6% of cases, but several patients had were found to have both HAART-induced 
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liver disease as well as chronic viral hepatitis or alcoholic liver disease.   When mean pre-
HAART LFTs were compared with mean post-HAART LFTs, significant elevations of 
approximately 50% were observed (p<0.0001).  Other causes of CLD (chronic hepatitis B 
and  NAFLD) accounted for under 5% of all cases in our study population. 
We identified several predictors of CLD in our study using univariate analysis, 
including older age, male gender, history of alcohol abuse, HIV exposure (through MSM, 
IDU, or heterosexual contact), positive HCV serology, treatment with HAART, and 
diagnosis of AIDS.  As has been reported in many previous studies, age appears to be an 
important factor driving the development of chronic liver disease.  Since the advent of 
HAART, HIV-infected patients are enjoying greater longevity but are also more likely to 
develop long-term complications from chronic disease.  In our cohort, male gender was 
also significantly associated with risk of CLD.  This could be due to the fact that alcohol 
abuse was more common in men; we found that 41% of males had a history of alcohol 
abuse, compared with only 22% of females.  Additionally, men have a worse long-term 
prognosis with HCV infection.  Regarding HIV exposure, intravenous drug use was 
likely associated with CLD due to shared routes of transmission between HIV and HCV.  
AIDS diagnosis was found to be a predictor of CLD, which suggests that the extremely 
immunocompromised state in these patients renders them more susceptible to comorbid 
disease.  As expected, our study also confirmed that alcohol abuse and positive HCV 
serology were strong predictors of chronic liver disease.  Although HAART was found to 
be a predictor of CLD, it is possible that age acted as a confounding factor, as the mean 
age of patients on HAART was slightly higher that that of patients not on HAART (45 
years versus 43 years). 
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In multivariate analysis, we found that alcohol abuse and HCV status remained 
significant independent risk factors for CLD in all patients.  When we looked at patients 
with HCV infection only, we found that HAART remained as the only significant 
predictor of CLD.  It can be speculated that these patients might have had elevated ALT 
only, which their physicians were willing to tolerate given the benefit of antiretroviral 
therapy in their HIV care.  
We found that preventive care and treatment for CLD were being overlooked in a 
substantial proportion of patients in our study.  With regards to immunization, 
pneumococcal and influenza vaccines were provided in approximately three-fourths of 
patients.  However, these numbers varied quite widely by clinic (53% to 95% for the 
pneumococcal vaccine, and 71% to 91% for the influenza vaccine.)  Vaccinations for 
hepatitis A and B were provided to only half of all eligible patients, and ranged from 32% 
to 74% for the HAV vaccine and 33% to 79% for the HBV vaccine depending on clinic.  
Furthermore, these numbers included even those patients who had received only one dose 
of these vaccines, which may not actually be sufficient to confer immunity.     
The immunocompromised state that develops in HIV infection puts patients at 
increased risk for morbidity and mortality from infections that can usually be prevented 
by vaccination, such as pneumococcal pneumonia, influenza, hepatitis A, and hepatitis B.  
As was shown in our study, many patients already have underlying liver disease caused 
by HCV or alcoholic hepatitis and are at increased risk of decompensation if they are 
exposed to HBV or HAV.  There is also evidence that HIV-infected individuals are less 
likely to clear HBV DNA and are at increased risk of chronic infection [61].  Although 
concerns have been raised about the safety of vaccination in HIV-positive patients, 
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specifically the risk of activating the immune system and the potential for accelerating 
HIV replication and disease progression, the benefits of vaccine administration appear to 
outweigh the risks.  
We also found that only a very small percentage of this population underwent 
treatment for their CLD.  Of the patients that had positive HCV or HBV serologies, only 
3.6% were treated with interferon, ribavirin, lamivudine, adefovir, or Cellcept.  Once 
again, this proportion varied broadly by clinic (0% to 8.4%), with the highest percentage 
of patients treated at Nathan Smith Clinic.  A similarly small proportion of patients were 
followed by a gastroenterologist (3.7%) for specialty care.  
Our study has several limitations.  First, we admit biases derived from the 
retrospective design of the study and the lack of uniform interpretation of data.  We did 
not interview patients, and data such as liver function tests, serologies, alcohol intake, 
and imaging studies were not collected in a routine fashion.  A considerable amount of 
data were missing in several categories, such as race and ethnicity, since these categories 
depended on individual physicians’ history and note-taking.  Other categories, such as 
HIV exposure, were self-reported by patients, and involved disclosure of certain lifestyle 
choices, such as illicit drug use or homosexual contact.  Due to the sensitive nature of 
these activities and the stigmas that sometimes accompany them, patients may have 
chosen to withhold their histories from their physicians.  Because of underreported and 
missing information, therefore, it is possible that our study underestimates the prevalence 
of many population characteristics.  Second, our case definition for chronic liver disease 
(taken from the New Haven County Liver Study) had certain inherent limitations.  
Physicians in these clinics did not routinely order imaging studies, biopsies or collection 
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of liver function tests; therefore, our results may again be an underestimation of the 
prevalence of chronic liver disease in this population.  Third, we studied a specific 
population of HIV-positive individuals in New Haven County, and our results may not be 
generalizable to other locales.  Finally, given the fact that post-HAART LFTs were 50% 
higher than pre-HAART LFTs, the NHCLS definition may be overly sensitive in this 
population and affected by the impact of ART on LFT measurements. 
In conclusion, the burden of chronic liver disease in HIV-infected populations is 
substantial and may even be underestimated in our study.  A large number of these 
patients are coinfected with hepatitis C and/or have a history of alcohol abuse, and the 
majority of them are not followed by gastroenterology practices.  Because HIV is known 
to accelerate the progression from hepatitis to cirrhosis [38-41], treatment for HCV with 
antivirals such as interferon and ribavirin must be considered a priority for coinfected 
patients and should be provided at the earliest possible time.  Strategies aimed at the 
reduction of alcohol consumption are extremely important components of care, and 
particularly relevant in patients who have a history of intravenous drug use, given that 
they may be more prone to the abuse of substances.  Although HAART-induced liver 
toxicity has been raised as a concern in this population, the benefits of antiretroviral 
therapy far outweigh the risks and should be considered in all patients.    
Preventive care is also of utmost importance in this population.  The United States 
Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA) have 
made recommendations that should guide physicians in providing immunizations to HIV 
positive patients.  The guidelines suggest that the pnemococcal vaccine should be 
provided to all adults and children at the time when CD4 count is greatest, with a single 
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revaccination after five years.  Annual influenza vaccination is recommended in all HIV 
positive patients, regardless of CD4 count, and routine screening and immunization 
against HBV is recommended for all HIV-infected adults.  With regards to the HAV 
vaccine, the current guidelines state that any patient with existing chronic liver disease or 
certain risk factors (chronic HBV or HCV, homosexual contact, IDU, or hemophilia) 
should be vaccinated either early in the course of HIV infection or following immune 
reconstitution on HAART. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 27
REFERENCES 
 
 
1.  Glynn M, Rhodes P.  2005.  Estimated HIV prevalence in the United States at the end 
of 2003. National HIV Prevention Conference.  Abstract 595. (Abstr)
 
2. Centers for Disease Control and Prevention (CDC).  2004.  HIV/AIDS surveillance 
report.  US Department of Health and Human Services, CDC, 2005.  Volume 16.  
 
3. Rutherford GW, Lifson AR, Hessol NA, Darrow WW, O'Malley PM et al.  1990.  
Course of HIV-I infection in a cohort of homosexual and bisexual men: an 11 year follow 
up study.  BMJ  301(6762):1183-1188. 
 
4. Centers for Disease Control and Prevention (CDC).  1987.  MMWR - Morbidity & 
Mortality Weekly Report 36:35. 
 
5. Hughes MD, Stein DS, Gundacker HM, Valentine FT, Phair JP et al.  1994.  Within-
subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency 
virus infection: implications for patient monitoring.  J Infect Dis 169(1):28-36. 
 
6. Centers for Disease Control and Prevention (CDC).  2005.  Trends in HIV/AIDS 
diagnoses--33 states, 2001-2004.   MMWR - Morbidity & Mortality Weekly Report 
54(45):1149-1153. 
 
7. Kaiser Family Foundation, Key Facts: Latinos and HIV/AIDS.  2003.  Available at 
http://www.kff.org/hivaids. 
 
8.  Kaiser Family Foundation, Key Facts: African Americans and HIV/AIDS.  2003.  
Available at http://www.kff.org/hivaids. 
 
9. Centers for Disease Control and Prevention (CDC).  2002.  HIV/AIDS Update: A 
Glance at the Epidemic.  US Department of Health and Human Services, CDC.   
 
10. Centers for Disease Control and Prevention (CDC).  2003.  HIV/AIDS Surveillance 
Supplemental Report, MMWR - Morbidity & Mortality Weekly Report  9:2. 
 
11. Singh GK, Hoyert DL.  2000.  Social epidemiology of chronic liver disease and 
cirrhosis mortality in the United States, 1935-1997: trends and differentials by ethnicity, 
socioeconomic status, and alcohol consumption. Human Biology. 72(5):801-820. 
 
12. Vong S, Bell BP. 2004.  Chronic liver disease mortality in the United States, 1990-
1998.  Hepatology 39(2):476-83. 
 
13. Wakim-Fleming J, Mullen KD.  2005.  Long-term management of alcoholic liver 
disease.  Clinics in Liver Disease  9(1):135-49. 
 
 
 28
14. Ramstedt M.  2001.  Per capita alcohol consumption and liver cirrhosis mortality in 
14 European countries, Addiction 96(2001): S19–S33. 
 
15. Marbet UA, Bianchi L, Meury U, Stalder GA.  1987.  Long-term histological 
evaluation of the natural history and prognostic factors of alcoholic liver disease.  Journal 
of Hepatology. 4(3):364-72. 
 
16. Becker U, Deis A, Sorensen TI, Gronbaek M, Borch-Johnsen K, et al.  1996.  
Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective 
population study. Hepatology 23(5):1025–1029. 
 
17. Moshage H.  2001.  Alcoholic liver disease: a matter of hormones?  J Hepatology 
35(1):130–133. 
 
18. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, et al.  1992.  The 
natural history of community-acquired hepatitis C in the United States. The Sentinel 
Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 327:1899-905. 
 
19.  Alter MJ.  1997.  Epidemiology of hepatitis C. Hepatology 26(3 suppl 1):S62-5. 
 
20. Davis GL. 1999.  Combination treatment with interferon and ribavirin for chronic 
hepatitis C. Clin Liver Dis 3:811-26. 
 
21. Befeler AS, Di Bisceglie AM.  2000.  Hepatitis B.  Infect Dis Clin North Am 14:617-
32. 
 
22. Corrao G, Arico S.  1998.  Independent and combined action of hepatitis C virus 
infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 
27:914-919, 2108-2113. 
 
23. Yuan JM, Govindarajan S, Arakawa K, Yu MC.  2004.  Synergism of alcohol, 
diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites 
in the U.S. Cancer. 101(5):1009-1017. 
 
24.  Manno M, Camma C, Schepis F, Bassi F, Gelmini R et al.  2004.  Natural history of 
chronic HBV carriers in northern Italy: morbidity and mortality after 30 years.   
Gastroenterology 127(3):756-63. 
 
25.  Villeneuve JP, Desrochers M, Infante-Rivard C, Willems B, Raymond G et al.  1994.   
A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive 
carriers in Montreal.  Gastroenterology 106(4):1000-5. 
 
26.  Centers for Disease Control and Prevention. 2002.  Sexually transmitted diseases 
treatment guidelines 2002. MMWR - Morbidity & Mortality Weekly Report  Recomm Rep 
51(RR-6):1-78. 
 
 
 29
27. Clark JM, Brancati FL, Diehl AM.  2002.  Nonalcoholic fatty liver disease. 
Gastroenterology 122:1649– 57. 
 
28. Ruhl CE, Everhart JE. 2003.  Determinants of the association of overweight with 
elevated serum alanine aminotransferase activity in the United States. Gastroenterology 
124:71– 9 
 
29.  Kemmer NM, Xiao SY, Singh H.  2001.   High Prevalence of NASH among 
Mexican American females with type II diabetes mellitus. 102nd Annual meeting of the 
American Gastroenterology Association (AGA). (Abstr)
 
30. Charlton M, Kasparova P, Weston S, Lindor K, Maor-Kendler Y, et al.  2001. 
Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver 
Transpl 7:608-614. 
 
31. Centers for Disease Control and Prevention (CDC). HIV-AIDS Surveillance Report 
1985-2002, United States. US Department of Health and Human Services, CDC, 2003. 
 
32. Lee LM, Karon JM, Selik R, Neal JJ, Fleming PL.  2001.  Survival after AIDS 
diagnosis in adolescents and adults during the treatment era, United States, 1984-1997.  
JAMA 285(10):1308-15. 
 
33. Bica I, McGovern B, Dhar R, Stone D, McGowan K, et al.  2001.  Increasing 
mortality due to end-stage liver disease in patients with human immuno-deficiency virus 
infection.  Clinical Infectious Diseases, 32(3):492-7. 
 
34. Staples CT Jr, Rimland D, Dudas D.  1999.  Hepatitis C in the HIV Atlanta Veterans 
Affairs Medical Center Cohort Study (HAVACS): the effect of coinfection on survival.  
Clinical Infectious Diseases 29(1):150-4. 
 
35. Sulkowski M.  1998.  HIV and hepatitis C virus co-infection.  The Hopkins HIV 
Report: a Bimonthly Newsletter for Healthcare Providers 10(6):8, 12. 
 
36. Lauer GM. Walker BD.  2001.  Hepatitis C virus infection.  NEJM  345(1):41-52. 
 
37. Wasley A. Alter MJ.  2000.  Epidemiology of hepatitis C: geographic differences and 
temporal trends.  Seminars in Liver Disease 20(1):1-16. 
 
38. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, et al.  1999.  Liver 
fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected 
patients: The Multivirc Group.  Hepatology 30(4):1054-8. 
 
39. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, et al.  1993.  Natural 
history of hepatitis C virus infection in multitransfused hemophiliacs: effect of 
coinfection with human immunodeficiency virus: The Multicenter Hemophilia Cohort 
Study.  J Acquir Immune Defic Syndr 6(6):602-10.   
 
 30
 
40. Pol S, Lamorthe B, Thi NT, Thiers V, Carnot F, et al.  1998.  Retrospective analysis 
of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of 
drug users.  J Hepatol 28(6):945-950. 
 
41. Cacoub P, Geffray L, Rosenthal E, Perronne C, Veyssier P, et al.  2001.  Mortality 
among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular 
carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious 
Diseases, in 1995 and 1997.  Clin Infect Dis 32(8):1207-14. 
 
42. Daar ES, Lynn H, Donfield S, Gomperts E, O'Brien SJ, et al.  2001.  Hepatitis C virus 
load is associated with human immunodeficiency virus type 1 disease progression in 
hemophiliacs.  J Infect Dis 183(4):589-95. 
 
43. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, et al.  2000.  Clinical 
progression, survival, and immune recovery during antiretroviral therapy in patients with 
HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study.  Lancet 56(9244): 
1800-5. 
 
44. Yoo TW, Donfield S, Lail A, Lynn HS, Daar ES.  2005.  Effect of hepatitis C virus 
(HCV) genotype on HCV and HIV-1 disease.  J Infect Dis 191(1):4-10. 
 
45. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL.  2002.  Hepatitis C 
and progression of HIV disease.  JAMA 288(2):199-206. 
 
46. Dorrucci M, Pezzotti P, Phillips AN, Lepri AC, Rezza G. 1995.  Coinfection of 
hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian 
Seroconversion Study.  J Infect Dis 172(6):1503-8. 
 
47. Tedaldi EM, Baker RK, Moorman AC, Alzola CF, Furhrer J, et al.  2003.  Influence 
of coinfection with hepatitis C virus on morbidity and mortality due to human immuno-
deficiency virus infection in the era of highly active antiretroviral therapy.  Clin Infect 
Dis 36(3):363-7. 
 
48. Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, et al.  1999.  
Influence of human immunodeficiency virus infection on chronic hepatitis B in 
homosexual men. Hepatology 29:1306-1310. 
 
49.. Thio CL, Seaberg EC, Skolasky R Jr., Phair J, Visscher B, et al.  2002.  HIV-1, 
hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study 
(MACS). Lancet 360:1921– 6. 
 
50. Dieterich DT.  2003.  Human immunodeficiency virus and liver: lessons learned and 
still to be learned. Semin Liver Dis 23(2):107– 14. 
 
 
 31
51. Servoss JC, Kitch D, Andersen J.  2003.  Predictors of antiretroviral-related 
hepatotoxicity in the adult AIDS Clinical Trials Group (AACTG). Hepatology 39(Suppl 
1):189. (Abstr)  
 
52. Saves M, Vandentorren S, Daucourt V, Marimoutou C, Dupon M, et al.  1999.  
Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral 
combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidemiologie Clinique de 
Sida en Aquitaine (GECSA).  AIDS 13(17):F115-21. 
 
53. Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, et al. 2003.  Effect of 
antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus 
coinfection.  Lancet 362(9397):1708-13. 
 
54. Conigliaro J, Gordon AJ, McGinnis KA, Rabeneck L, Justice AC.  2003.  How 
harmful is hazardous alcohol use and abuse in HIV infection: do providers know who is 
at risk? J Acquir Immune Defic Syndr 33: 521–525. 
 
55. Cook RL, Sereika SM, Hunt SC, Woodward WC, Erlen JA, Conigliaro J.  2001.  
Problem drinking and medication adherence among persons with HIV infection. J Gen 
Intern Med 16: 83–88. 
 
56. Wagner JH, Justice AC, Chesney M, Sinclair G, Weissman S, Rodriguez-Barradas M.  
2001.  Patient- and provider-reported adherence: towards a clinically useful approach to 
measuring anti-retroviral adherence. J Clin Epidemiol 54: S91–S98. 
 
57. Conigliaro J, Madenwald T, Bryant K, Braithwaite S, Gordon A, et al.  2004.  The 
Veterans Aging Cohort Study: observational studies of alcohol use, abuse, and outcomes 
among human immunodeficiency virus-infected veterans.  Alcoholism: Clinical & 
Experimental Research 28(2):313-21. 
 
58.  Ong JP. Younossi ZM.  2005.  Approach to the diagnosis and treatment of 
nonalcoholic fatty liver disease. Clinics in liver disease 9(4):617 -34, vi.   
 
59. Duong M, Petit JM, Piroth L, Grappin M, Buisson M, et al.  2001.  Association 
between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C 
virus-coinfected patients undergoing antiretroviral therapy.  J Acquir Immune Defic 
Syndr 27:245– 50. 
 
60.  Centers for Disease Control and Prevention (CDC). 1992.  1993 Revised 
Classification System for HIV Infection and Expanded Surveillance Case Definition for 
AIDS Among Adolescents and Adults.  MMWR - Morbidity & Mortality Weekly Report  
41: RR-17. 
 
61. Hadler SC, Judson FN, O'Malley PM, Altman NL, Penley K, et al.  1991.  Outcome 
of Hepatitis B infection in homosexual men and its relation to prior human 
immunodeficiency virus infection. J Infect Dis 163(3):454-459. 
 
